- Home
- RPRX vs EQR Comparison
RPRX vs EQR Comparison
Compare RPRX & EQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | EQR |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 24.3B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RPRX | EQR |
|---|---|---|
| Price | $52.97 | $64.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $51.40 | ★ $69.63 |
| AVG Volume (30 Days) | ★ 2.8M | 2.5M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | 1.90% | ★ 4.29% |
| EPS Growth | N/A | ★ 8.09 |
| EPS | ★ 0.67 | 0.24 |
| Revenue | $2,378,193,000.00 | ★ $2,701,075,000.00 |
| Revenue This Year | $38.63 | $4.07 |
| Revenue Next Year | $4.73 | $3.14 |
| P/E Ratio | ★ $79.66 | $271.29 |
| Revenue Growth | ★ 5.06 | 4.76 |
| 52 Week Low | $32.15 | $57.57 |
| 52 Week High | $53.47 | $71.52 |
Technical Indicators
Market Signals| Indicator | RPRX | EQR |
|---|---|---|
| Relative Strength Index (RSI) | 68.50 | 50.06 |
| Support Level | $35.35 | $63.61 |
| Resistance Level | N/A | $66.51 |
| Average True Range (ATR) | 1.08 | 1.28 |
| MACD | 0.21 | -0.18 |
| Stochastic Oscillator | 81.19 | 32.11 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 318 apartment communities with over 86,000 units and is developing three additional properties with 935 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.